Program
ABP-745
A development code. Also written as “ABP-745 Dose A”, “ABP-745 Dose B” and “ABP-745 Dose C”.
Its studies are mostly in Gout · Atherosclerosis, led by Atom Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atom Therapeutics | 31 open or running | phase 2since Aug 13, 2025 | Jan 29, 2024 | Jan 2028phase 2 · NCT07303777 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2024First study: phase 1 study in GoutFirst studyNCT06258213 · 90 enrolled · United States
- Aug 13, 2025Phase 2 study in GoutNCT07145229 · 479 enrolled · United States, Australia, China
- Dec 23, 2025Phase 2 study in Atherosclerosis Cardiovascular DiseaseNCT07303777 · 200 planned · United States, Australia, China
Ahead
- Jan 2028Primary completion: phase 2 study in Atherosclerosis Cardiovascular DiseaseNCT07303777
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07303777Atherosclerosis Cardiovascular Disease · United States, Australia, China | 2 | Recruiting | Jan 2028 | 200 |
| NCT07145229Gout · United States, Australia, China | 2 | Completed | Jul 14, 2026 | 479 |
| NCT06258213Gout · United States | 1 | Completed | Jul 29, 2024 | 90 |
How it is read
Names in the registry
- “ABP-745 Dose A”, 2 entries
- “ABP-745 Dose B”, 2 entries
- “ABP-745 Dose C”, 1 entry
- “ABP-745”, 1 entry
Codes read as this program: ABP745.
Conditions, from the studies’ own filings
- Gout, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.